Gemcitabine plus metronomic 5-fluorouracil or capecitabine as asecond-/third-line chemotherapy in advanced adrenocortical carcinoma: amulticenter phase II study.

Giuseppe Badalamenti, Giuseppe Badalamenti, Silvia De Francia, Barbara Zaggia, Riccardo Ratti, Emmanouil Kalomirakis, Luigi Dogliotti, Sabrina Del Buono, Fulvia Daffara, Marco Volante, Bruno Vincenzi, Alfredo Berruti, Mauro Papotti, Massimo Terzolo, Anna Ferrero, Alberto Angeli, Daniele Santini, Paola Sperone, Adriano Priola, Chiara IntriviciChiara Intrivici

Risultato della ricerca: Article

78 Citazioni (Scopus)

Abstract

Adrenocortical carcinoma (ACC) is a rare neoplasm characterized by poorprognosis. First-line systemic treatments in advanced disease include mitotane,either alone or in combination with chemotherapy. Studies evaluating second-line therapy options have obtained disappointing results. This trial assessed theactivity and toxicity of gemcitabine plus metronomic fluoropyrimidines in heavilypretreated advanced ACC patients. From 1998 to 2008, 28 patients with advancedACC progressing after mitotane plus one or two systemic chemotherapy lines wereenrolled. They received a combination of i.v. gemcitabine (800 mg/m(2), on days 1and 8, every 21 days) and i.v. 5-fluorouracil protracted infusion (200mg/m(2)/daily without interruption until progression) in the first six patients, or oral capecitabine (1500 mg/daily) in the subsequent patients. Mitotaneadministration was maintained in all cases. The rate of non-progressing patients after 4 months of treatment was 46.3%. A complete response was observed in 1patient (3.5%); 1 patient (3.5%) obtained a partial regression, 11 patients(39.3%) obtained a disease stabilization and 15 patients (53.7%) progressed.Treatment was well tolerated, with grade III and IV toxicities consisting ofleukopenia in six patients (21.4%), thrombocytopenia in one patient (3.5%), andmucositis in one patient (3.5%). Median time to progression and overall survival in the patient population were 5.3 (range: 1-43) and 9.8 months (range: 3-73)respectively. Gemcitabine plus metronomic fluoropyrimidines is a well-toleratedand moderately active regimen in heavily pretreated ACC patients.
Lingua originaleEnglish
pagine (da-a)445-453
Numero di pagine9
RivistaEndocrine-Related Cancer
Volume17
Stato di pubblicazionePublished - 2010

Fingerprint

gemcitabine
Adrenocortical Carcinoma
Fluorouracil
Drug Therapy
Mitotane
Capecitabine

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Oncology
  • Endocrinology
  • Cancer Research

Cita questo

Gemcitabine plus metronomic 5-fluorouracil or capecitabine as asecond-/third-line chemotherapy in advanced adrenocortical carcinoma: amulticenter phase II study. / Badalamenti, Giuseppe; Badalamenti, Giuseppe; De Francia, Silvia; Zaggia, Barbara; Ratti, Riccardo; Kalomirakis, Emmanouil; Dogliotti, Luigi; Del Buono, Sabrina; Daffara, Fulvia; Volante, Marco; Vincenzi, Bruno; Berruti, Alfredo; Papotti, Mauro; Terzolo, Massimo; Ferrero, Anna; Angeli, Alberto; Santini, Daniele; Sperone, Paola; Priola, Adriano; Intrivici, Chiara; Intrivici, Chiara.

In: Endocrine-Related Cancer, Vol. 17, 2010, pag. 445-453.

Risultato della ricerca: Article

Badalamenti, G, Badalamenti, G, De Francia, S, Zaggia, B, Ratti, R, Kalomirakis, E, Dogliotti, L, Del Buono, S, Daffara, F, Volante, M, Vincenzi, B, Berruti, A, Papotti, M, Terzolo, M, Ferrero, A, Angeli, A, Santini, D, Sperone, P, Priola, A, Intrivici, C & Intrivici, C 2010, 'Gemcitabine plus metronomic 5-fluorouracil or capecitabine as asecond-/third-line chemotherapy in advanced adrenocortical carcinoma: amulticenter phase II study.', Endocrine-Related Cancer, vol. 17, pagg. 445-453.
Badalamenti, Giuseppe ; Badalamenti, Giuseppe ; De Francia, Silvia ; Zaggia, Barbara ; Ratti, Riccardo ; Kalomirakis, Emmanouil ; Dogliotti, Luigi ; Del Buono, Sabrina ; Daffara, Fulvia ; Volante, Marco ; Vincenzi, Bruno ; Berruti, Alfredo ; Papotti, Mauro ; Terzolo, Massimo ; Ferrero, Anna ; Angeli, Alberto ; Santini, Daniele ; Sperone, Paola ; Priola, Adriano ; Intrivici, Chiara ; Intrivici, Chiara. / Gemcitabine plus metronomic 5-fluorouracil or capecitabine as asecond-/third-line chemotherapy in advanced adrenocortical carcinoma: amulticenter phase II study. In: Endocrine-Related Cancer. 2010 ; Vol. 17. pagg. 445-453.
@article{159368dda86246a6afe1dc351543f55a,
title = "Gemcitabine plus metronomic 5-fluorouracil or capecitabine as asecond-/third-line chemotherapy in advanced adrenocortical carcinoma: amulticenter phase II study.",
abstract = "Adrenocortical carcinoma (ACC) is a rare neoplasm characterized by poorprognosis. First-line systemic treatments in advanced disease include mitotane,either alone or in combination with chemotherapy. Studies evaluating second-line therapy options have obtained disappointing results. This trial assessed theactivity and toxicity of gemcitabine plus metronomic fluoropyrimidines in heavilypretreated advanced ACC patients. From 1998 to 2008, 28 patients with advancedACC progressing after mitotane plus one or two systemic chemotherapy lines wereenrolled. They received a combination of i.v. gemcitabine (800 mg/m(2), on days 1and 8, every 21 days) and i.v. 5-fluorouracil protracted infusion (200mg/m(2)/daily without interruption until progression) in the first six patients, or oral capecitabine (1500 mg/daily) in the subsequent patients. Mitotaneadministration was maintained in all cases. The rate of non-progressing patients after 4 months of treatment was 46.3{\%}. A complete response was observed in 1patient (3.5{\%}); 1 patient (3.5{\%}) obtained a partial regression, 11 patients(39.3{\%}) obtained a disease stabilization and 15 patients (53.7{\%}) progressed.Treatment was well tolerated, with grade III and IV toxicities consisting ofleukopenia in six patients (21.4{\%}), thrombocytopenia in one patient (3.5{\%}), andmucositis in one patient (3.5{\%}). Median time to progression and overall survival in the patient population were 5.3 (range: 1-43) and 9.8 months (range: 3-73)respectively. Gemcitabine plus metronomic fluoropyrimidines is a well-toleratedand moderately active regimen in heavily pretreated ACC patients.",
keywords = "adrenocortical carcinoma",
author = "Giuseppe Badalamenti and Giuseppe Badalamenti and {De Francia}, Silvia and Barbara Zaggia and Riccardo Ratti and Emmanouil Kalomirakis and Luigi Dogliotti and {Del Buono}, Sabrina and Fulvia Daffara and Marco Volante and Bruno Vincenzi and Alfredo Berruti and Mauro Papotti and Massimo Terzolo and Anna Ferrero and Alberto Angeli and Daniele Santini and Paola Sperone and Adriano Priola and Chiara Intrivici and Chiara Intrivici",
year = "2010",
language = "English",
volume = "17",
pages = "445--453",
journal = "Endocrine-Related Cancer",
issn = "1351-0088",
publisher = "Society for Endocrinology",

}

TY - JOUR

T1 - Gemcitabine plus metronomic 5-fluorouracil or capecitabine as asecond-/third-line chemotherapy in advanced adrenocortical carcinoma: amulticenter phase II study.

AU - Badalamenti, Giuseppe

AU - Badalamenti, Giuseppe

AU - De Francia, Silvia

AU - Zaggia, Barbara

AU - Ratti, Riccardo

AU - Kalomirakis, Emmanouil

AU - Dogliotti, Luigi

AU - Del Buono, Sabrina

AU - Daffara, Fulvia

AU - Volante, Marco

AU - Vincenzi, Bruno

AU - Berruti, Alfredo

AU - Papotti, Mauro

AU - Terzolo, Massimo

AU - Ferrero, Anna

AU - Angeli, Alberto

AU - Santini, Daniele

AU - Sperone, Paola

AU - Priola, Adriano

AU - Intrivici, Chiara

AU - Intrivici, Chiara

PY - 2010

Y1 - 2010

N2 - Adrenocortical carcinoma (ACC) is a rare neoplasm characterized by poorprognosis. First-line systemic treatments in advanced disease include mitotane,either alone or in combination with chemotherapy. Studies evaluating second-line therapy options have obtained disappointing results. This trial assessed theactivity and toxicity of gemcitabine plus metronomic fluoropyrimidines in heavilypretreated advanced ACC patients. From 1998 to 2008, 28 patients with advancedACC progressing after mitotane plus one or two systemic chemotherapy lines wereenrolled. They received a combination of i.v. gemcitabine (800 mg/m(2), on days 1and 8, every 21 days) and i.v. 5-fluorouracil protracted infusion (200mg/m(2)/daily without interruption until progression) in the first six patients, or oral capecitabine (1500 mg/daily) in the subsequent patients. Mitotaneadministration was maintained in all cases. The rate of non-progressing patients after 4 months of treatment was 46.3%. A complete response was observed in 1patient (3.5%); 1 patient (3.5%) obtained a partial regression, 11 patients(39.3%) obtained a disease stabilization and 15 patients (53.7%) progressed.Treatment was well tolerated, with grade III and IV toxicities consisting ofleukopenia in six patients (21.4%), thrombocytopenia in one patient (3.5%), andmucositis in one patient (3.5%). Median time to progression and overall survival in the patient population were 5.3 (range: 1-43) and 9.8 months (range: 3-73)respectively. Gemcitabine plus metronomic fluoropyrimidines is a well-toleratedand moderately active regimen in heavily pretreated ACC patients.

AB - Adrenocortical carcinoma (ACC) is a rare neoplasm characterized by poorprognosis. First-line systemic treatments in advanced disease include mitotane,either alone or in combination with chemotherapy. Studies evaluating second-line therapy options have obtained disappointing results. This trial assessed theactivity and toxicity of gemcitabine plus metronomic fluoropyrimidines in heavilypretreated advanced ACC patients. From 1998 to 2008, 28 patients with advancedACC progressing after mitotane plus one or two systemic chemotherapy lines wereenrolled. They received a combination of i.v. gemcitabine (800 mg/m(2), on days 1and 8, every 21 days) and i.v. 5-fluorouracil protracted infusion (200mg/m(2)/daily without interruption until progression) in the first six patients, or oral capecitabine (1500 mg/daily) in the subsequent patients. Mitotaneadministration was maintained in all cases. The rate of non-progressing patients after 4 months of treatment was 46.3%. A complete response was observed in 1patient (3.5%); 1 patient (3.5%) obtained a partial regression, 11 patients(39.3%) obtained a disease stabilization and 15 patients (53.7%) progressed.Treatment was well tolerated, with grade III and IV toxicities consisting ofleukopenia in six patients (21.4%), thrombocytopenia in one patient (3.5%), andmucositis in one patient (3.5%). Median time to progression and overall survival in the patient population were 5.3 (range: 1-43) and 9.8 months (range: 3-73)respectively. Gemcitabine plus metronomic fluoropyrimidines is a well-toleratedand moderately active regimen in heavily pretreated ACC patients.

KW - adrenocortical carcinoma

UR - http://hdl.handle.net/10447/55826

M3 - Article

VL - 17

SP - 445

EP - 453

JO - Endocrine-Related Cancer

JF - Endocrine-Related Cancer

SN - 1351-0088

ER -